article = {IJRGM-2022-2-102}
title = {Hematopoietic Stem Cell Transplantation in Juvenile Myelomonocytic Leukemia: A Case Report and Literature Review}
journal = {International Journal of Regenerative Medicine}
year = {2022}
issn = {2613-5914}
doi = {http://dx.doi.org/10.31487/j.RGM.2022.02.02}
url = {https://www.sciencerepository.org/hematopoietic-stem-cell-transplantation_RGM-2022-2-102 
author = {Malek Benakli,Redhouane Ahmed Nacer,Farih Mehdid,Mounira Baazizi,Nadia Rahmoune,Dina Ait Ouali,Hanane Bouarab,Sara Zerkout,Fouzia Louar,Rose Marie Hamladji,}
keywords = {Juvenile myelomonocytic leukemia, myelodysplastic/myeloproliferative diseases, pediatric leukemia, allogeneic hematopoietic stem cell transplantation}
abstract ={Juvenile myelomonocytic leukemia (JMML) is a rare hematological malignancy of early childhood, classified by the World Health Organization as a myelodysplastic/myeloproliferative disease and is associated with a poor prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative treatment. A two-year-old male child was diagnosed with JMML and was given induction chemotherapy. One year after diagnosis, the patient received allogeneic hematopoietic stem cell transplantation from an HLA sibling donor after a myeloablative conditioning regimen. The patient remained free of disease after 5 years of follow-up, healthy, with complete clinical, immunologic and hematologic recovery, without signs of JMML. Transplantation is the only modality to achieve a cure in JMML patients. The most widely practiced approach is the use of bone marrow or peripheral blood stem cells after a myeloablative conditioning regimen. Post-transplant monitoring chimerism can help identify the patients who are at risk of relapse.}